Biomarin Pharmaceutical Inc logo

Biomarin Pharmaceutical Inc

MEX:BMRN (USA)  
MXN 1557.87 (0%) May 27
70.58
P/B:
2.82
Market Cap:
MXN 239.53B ($ 14.38B)
Enterprise V:
MXN 240.36B ($ 14.43B)
Volume:
-
Avg Vol (2M):
371.00
Also Trade In:
Volume:
-
Avg Vol (2M):
371.00

Business Description

Description
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Name Current Vs Industry Vs History
Cash-To-Debt 0.95
Equity-to-Asset 0.74
Debt-to-Equity 0.22
Debt-to-EBITDA 3.05
Interest Coverage 10.68
Piotroski F-Score 7/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 5.49
Distress
Grey
Safe
Beneish M-Score -2.45
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
9-Day RSI 0.98
14-Day RSI 12.01
6-1 Month Momentum % 13.3
12-1 Month Momentum % -3.84

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.74
Quick Ratio 1.7
Cash Ratio 0.96
Days Inventory 735.25
Days Sales Outstanding 90.13
Days Payable 206.4

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1.2
Shareholder Yield % -0.02

Financials (Next Earnings Date:2024-07-31 Est.)

MEX:BMRN's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Biomarin Pharmaceutical Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil MXN) 42,314.363
EPS (TTM) (MXN) 18.239
Beta 0
Volatility % 23.56
14-Day RSI 12.01
14-Day ATR (MXN) 0.188864
20-Day SMA (MXN) 1557.87
12-1 Month Momentum % -3.84
52-Week Range (MXN) 1375 - 1620
Shares Outstanding (Mil) 189.88

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 7
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biomarin Pharmaceutical Inc Filings

Filing Date Document Date Form
No Filing Data

Biomarin Pharmaceutical Inc Stock Events

Financials Calendars
Event Date Price(MXN)
No Event Data

Biomarin Pharmaceutical Inc Frequently Asked Questions

What is Biomarin Pharmaceutical Inc(MEX:BMRN)'s stock price today?
The current price of MEX:BMRN is MXN1557.87. The 52 week high of MEX:BMRN is MXN1620.00 and 52 week low is MXN1375.00.
When is next earnings date of Biomarin Pharmaceutical Inc(MEX:BMRN)?
The next earnings date of Biomarin Pharmaceutical Inc(MEX:BMRN) is 2024-07-31 Est..
Does Biomarin Pharmaceutical Inc(MEX:BMRN) pay dividends? If so, how much?
Biomarin Pharmaceutical Inc(MEX:BMRN) does not pay dividend.

Press Release

Subject Date
No Press Release